eligibility_summary
Adults ≥18 with untreated CD20+ follicular lymphoma grade 1–3A, stage II–IV, ECOG 0–1 (2 if lymphoma‑related), measurable FDG‑avid disease needing therapy. Adequate organ function, LVEF>45%, life expectancy>3 mo, contraception, consent. Exclude grade 3B/transformed FL, CNS disease, prior checkpoint therapy, active autoimmune disease or steroids, ILD, transplants, recent/active other cancers, serious cardiac disease, active HBV/HCV, HIV, severe mAb allergy, or inability to consent.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II, first-line follicular lymphoma: rituximab + golcadomide, ± nivolumab. Interventions/mechanisms: Golcadomide (BMS-986369/CC-99282) is an oral CELMoD small molecule that binds cereblon (CRBN) E3 ligase to induce IKZF1/IKZF3 degradation, directly inhibiting malignant B cells and enhancing T- and NK-cell activation/cytokines. Rituximab is a chimeric anti-CD20 IgG1 monoclonal antibody that depletes CD20+ B cells via ADCC, CDC, and apoptosis. Nivolumab is a fully human IgG4 anti-PD-1 monoclonal antibody that releases checkpoint inhibition to restore antitumor T-cell activity. Cells/pathways targeted: CD20+ follicular B cells, CRBN–IKZF1/3 axis, PD-1/PD-L1 checkpoint, activation of T cells and NK cells in the FL microenvironment.